Benzinga | Nov 5, 2020 05:14PM EST

Biomarin Pharmaceutical Q3 EPS $4.01 May Not Compare To $1.29 Estimate, Sales $476.80M Beat $454.64M Estimate

Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $4.01 per share which beat the analyst consensus estimate of $1.29 by 210.85 percent. This is a 1236.67 percent increase over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $476.80 million which beat the analyst consensus estimate of $454.64 million by 4.87 percent. This is a 3.41 percent increase over sales of $461.10 million the same period last year.